Quick Answer
Royalty Pharma plc reported R&D Expense of $452.00 million for fiscal year 2025.
Royalty Pharma plc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $452.00M | +22500.0% |
| 2024 | $2.00M | -96.2% |
| 2023 | $52.00M | -70.6% |
| 2022 | $177.11M | -11.5% |
| 2021 | $200.08M | +661.1% |
| 2020 | $26.29M | -68.3% |
| 2019 | $83.04M | -78.9% |
| 2018 | $392.61M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $50.50M | +10000.0% | -83.2% |
| June 30, 2025 | $300.50M | +60000.0% | +495.0% |
| March 31, 2025 | $50.50M | +10000.0% | +10000.0% |
| September 30, 2024 | $500.0K | -99.0% | +0.0% |
| June 30, 2024 | $500.0K | +0.0% | +0.0% |
| March 31, 2024 | $500.0K | +0.0% | -99.0% |
| September 30, 2023 | $50.50M | +98.0% | +10000.0% |
| June 30, 2023 | $500.0K | -17.5% | +0.0% |
- Royalty Pharma plc showed an increase of +22500.0% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Royalty Pharma plc’s r&d expense has grown by 15.1% (from $392.61 million to $452.00 million).
- The most recent figure is from Royalty Pharma plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: